2012 News

12.17.2012 Press Release

Changes in Significant Shareholders

11.27.2012 Press Release

Santen Files for Manufacturing/Marketing Approval of its Anti-Allergic Ophthalmic Solution DE-114 (Generic name: Epinastine Hydrochloride)

11.27.2012 Press Release

Intravitreal VEGF Inhibitor "EYLEA (aflibercept) Solution for Intravitreal Injection" Released on the Market for the Treatment of Wet Age-Related Macular Degeneration

11.01.2012 Press Release

Santen Announces Financial Result for the Second Quarter ended September 30, 2012

11.01.2012 Press Release

Notice of Cancellation of Treasury Shares

10.03.2012 Press Release

Santen to Renew the Sante 40 OTC Eye Drop Series

09.28.2012 Press Release

Intravitreal VEGF Inhibitor "EYLEA Solution for Intravitreal Injection" and "EYLEA Intravitreal Injection KIT" Approved for the Treatment of Wet Age-Related Macular Degeneration in Japan

09.25.2012 Press Release

Notice on the Establishment of a New Sales and Marketing Company in China

09.25.2012 Press Release

Eisai and Santen Enter into Option Agreement for New Ophthalmic Drugs

08.30.2012 Press Release

Notification Regarding Result and Completion of Acquisition of Treasury Stock and Tender Offer of Treasury Stock

08.01.2012 Press Release

Santen Announces Financial Result for the First Quarter ended June 30, 2012

08.01.2012 Press Release

Notice of Acquisition and Tender Offer of Treasury Stock

07.04.2012 Press Release

Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)

06.25.2012 Press Release

FDA Approves enVista, a Single-Piece Intraocular Lens, Made from the Glistening-Free, Hydrophobic, Acrylic Material Developed by AVS

06.20.2012 Press Release

Notice on the Allotment of Stock Options (Stock Acquisition Rights)

05.08.2012 Press Release

Santen Announces Financial Results for the Year ended March 31, 2012

05.08.2012 Press Release

Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Directors

05.08.2012 Press Release

Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Corporate Officers

05.08.2012 Press Release

Notice of the Nominations for the members of the Board of Directors

05.08.2012 Press Release

Announcement of the conclusion of the agreement on co-promotion of VEGF Trap-Eye (aflibercept intravitreal injection)

03.09.2012 Press Release

Notice of the appointment of Corporate Officers

03.01.2012 Press Release

Santen to Launch Sante Medical Guard OTC Eye Drop

02.14.2012 Press Release

FDA Approves ZIOPTAN (tafluprost ophthalmic solution),Merck's Once-Daily, Preservative-Free Ophthalmic Medication

02.07.2012 Press Release

Santen Announces Financial Result for the Third Quarter ended December 31, 2011

02.07.2012 Press Release

Notice on the Establishment of Holding Company in Europe

01.24.2012 Press Release

Santen to Launch Nutritional Supplement Sante Lutax 20 + DHA